UBS Group
CRNX

UBS Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

UBS Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,000
Closed -$936K – 9600
2024
Q1 		$936K Buy
+20,000
New +$783K ﹤0.01% 4656

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's CRNX Position: Q2 2026 in Review

UBS Group reduced its Crinetics Pharmaceuticals (CRNX) stake by 1.9% in Q2 2026, selling an estimated $399K and leaving 561,165 shares worth $21M. The position accounts for ﹤0.01% of the portfolio, ranked #2629.

UBS Group first reported a position in CRNX in Q3 2018 and has held it in 30 quarters since. The position peaked at $42.3M in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • UBS Group held 561,165 shares of Crinetics Pharmaceuticals worth $21M as of Q2 2026.
  • UBS Group sold 10,734 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $399K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2629 holding.
  • UBS Group first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 30 quarters since.
  • UBS Group's Crinetics Pharmaceuticals position peaked at $42.3M in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.